Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy

Journal of Hepatology

Volumn 62, Issue 4, 2015, Pages 956-967

  Papatheodoridis, George V ^a   Chan, Henry Lik Yuen ^b   Hansen, Bettina E ^c   Janssen, Harry L A ^c,d   Lampertico, Pietro ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Entecavir; HCC risk score; Hepatitis B virus; Liver cancer; Tenofovir

Indexed keywords

ADEFOVIR; CLEVUDINE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ASIAN; CANCER RISK; CAUCASIAN; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PRIORITY JOURNAL; REVIEW; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; OUTCOME ASSESSMENT; RISK ASSESSMENT;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RISK ASSESSMENT;

EID: 84926407117     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.01.002     Document Type: Review

References (66)

1. R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya, and V. Aboyans Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2095 2128
2. G. Fattovich, F. Bortolotti, and F. Donato Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors J Hepatol 48 2008 335 352
3. D.Y. But, C.L. Lai, and M.F. Yuen Natural history of hepatitis-related hepatocellular carcinoma World J Gastroenterol 14 2008 1652 1656
4. A. Arzumanyan, H.M. Reis, and M.A. Feitelson Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma Nat Rev Cancer 13 2013 123 135
5. M.C. Kew Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma J Gastroenterol Hepatol 26 2011 144 152
6. W.K. Sung, H. Zheng, S. Li, R. Chen, X. Liu, and Y. Li Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma Nat Genet 44 2012 765 769
7. S.T. Toh, Y. Jin, L. Liu, J. Wang, F. Babrzadeh, and B. Gharizadeh Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations Carcinogenesis 34 2013 787 798
8. C.J. Chen, H.I. Yang, J. Su, C.L. Jen, S.L. You, and S.N. Lu Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
9. G. Chen, W. Lin, F. Shen, U.H. Iloeje, W.T. London, and A.A. Evans Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study Am J Gastroenterol 101 2006 1797 1803
10. S. Liu, H. Zhang, C. Gu, J. Yin, Y. He, and J. Xie Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis J Natl Cancer Inst 101 2009 1066 1082
11. H.L. Chan, A.Y. Hui, M.L. Wong, A.M. Tse, L.C. Hung, and V.W. Wong Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma Gut 53 2004 1494 1498
12. G.L. Wong, H.L. Chan, K.K. Yiu, J.W. Lai, V.K. Chan, and K.K. Cheung Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma Aliment Pharmacol Ther 37 2013 517 526
13. T.C. Tseng, C.J. Liu, H.C. Yang, T.H. Su, C.C. Wang, and C.L. Chen High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load Gastroenterology 142 2012 1140 1149
14. G.L. Wong, V.W. Wong, P.C. Choi, A.W. Chan, A.M. Chim, and K.K. Yiu Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B Gut 58 2009 111 117
15. H.P. Chen, J.J. Shieh, C.C. Chang, T.T. Chen, J.T. Lin, and M.S. Wu Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies Gut 62 2013 606 615
16. Y.F. Liaw, J.J. Sung, W.C. Chow, G. Farrell, C.Z. Lee, and H. Yuen Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
17. G.V. Papatheodoridis, P. Lampertico, S. Manolakopoulos, and A. Lok Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 2010 348 356
18. A.K. Singal, H. Salameh, Y.F. Kuo, and R.J. Fontana Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B Aliment Pharmacol Ther 38 2013 98 106
19. European Association For The Study Of The Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
20. Y.F. Liaw, J.H. Kao, T. Piratvisuth, H.L.Y. Chan, R.N. Chien, and C.J. Liu Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hep Intl 6 2012 531 561
21. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
22. T.T. Chang, C.L. Lai, Y.S. Kew, S.S. Lee, H.S. Coelho, and F.J. Carrilho Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
23. T.T. Chang, Y.F. Liaw, S.S. Wu, E. Schiff, K.H. Han, and C.L. Lai Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
24. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, and I.M. Jacobson Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
25. G.L. Wong, H.L. Chan, C.H. Mak, S.K. Lee, Z.M. Ip, and A.T. Lam Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis Hepatology 58 2013 1537 1547
26. T. Hosaka, F. Suzuki, M. Kobayashi, Y. Seko, Y. Kawamura, and H. Sezaki Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection Hepatology 58 2013 98 107
27. T. Su, Kao, Hu, Lin, Peng, and Chuang Reduction of hepatocellular carcinoma in hepatitis B-related cirrhosis patients with long-term entecavir therapy - an interim report of C-TEAM study Hepatology 58 2013 301A [abstract 189]
28. T. Kumada, H. Toyoda, T. Tada, S. Kiriyama, M. Tanikawa, and Y. Hisanaga Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis J Hepatol 58 2013 427 433
29. C.Y. Wu, J.T. Lin, H.J. Ho, C.W. Su, T.Y. Lee, and S.Y. Wang Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-A nationwide cohort study Gastroenterology 147 2014 143 151
30. W.R. Kim, T. Berg, R. Loomba, R. Aguilar Schall, P. Dinh, and L.J. Yee Long Term Tenofovir Disoproxil Fumarate (TDF) therapy and the risk of hepatocellular carcinoma J Hepatol 58 2013 S19 [abstract 43]
31. H.I. Yang, M.F. Yuen, H.L. Chan, K.H. Han, P.J. Chen, and D.Y. Kim Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score Lancet Oncol 12 2011 568 574
32. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
33. S.C. Yang, C.M. Lee, T.H. Hu, J.H. Wang, S.N. Lu, and C.H. Hung Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants J Antimicrob Chemother 68 2013 2154 2163
34. S.S. Kim, S.J. Ahn, S.Y. Park, G.W. Song, J.Y. Cheong, and S.W. Cho Virological response to entecavir is associated with low probability of developing hepatocellular carcinoma in chronic hepatitis B patients with cirrhosis J Hepatol 58 2013 S265 [abstract 652]
35. J.Y. Cho, Y.H. Paik, W. Sohn, H.C. Cho, G.Y. Gwak, and M.S. Choi Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease Gut 63 2014 1943 1950
36. R. Zoutendijk, J.G. Reijnders, F. Zoulim, A. Brown, D.J. Mutimer, and K. Deterding Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis Gut 62 2013 760 765
37. P. Arends, M.J. Sonneveld, R. Zoutendijk, I. Carey, A. Brown, and M. Fasano Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians Gut 2014 10.1136/gutjnl-2014-307023 [Epub ahead of print]
38. G.V. Papatheodoridis, S. Manolakopoulos, G. Touloumi, G. Nikolopoulou, M. Raptopoulou-Gigi, and C. Gogos Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort J Viral Hepat 2014 10.1111/jvh.12283 [Epub ahead of print]
39. H. Kobashi, Y. Miyake, F. Ikeda, T. Yasunaka, K. Nishino, and A. Moriya Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine Hepatol Res 41 2011 405 416
40. Y.S. Lim, S. Han, N.Y. Heo, J.H. Shim, H.C. Lee, and D.J. Suh Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine Gastroenterology 147 2014 152 161
41. Y. Lee Incidence and risk assessment for the development of hepatocellular carcinoma during long-term entecavir and lamivudine therapy in hepatitis B virus-related liver disease Hepatology 58 2013 1259A [abstract 2173]
42. S. Koklu, Y. Tuna, M.T. Gulsen, M. Demir, A.S. Koksal, and M.C. Kockar Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis Clin Gastroenterol Hepatol 11 2013 88 94
43. S. Goturk Virological suppression does not prevent the development of hepatocellular carcinoma in cirrhotic patients with genotype D hepatitis B infection Hepatology 58 2013 684A [abstract 990]
44. P. Lampertico, R. Soffredini, M. Viganò, E. Minola, G. Cologni, and M. Rizzi 5-year entecavir treatment in nuc-naïve, field-practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics J Hepatol 58 2013 S306 312 [abstract 755]
45. P. Lampertico, R. Soffredini, C. Yurdaydin, R. Idilman, G.V. Papatheodoridis, and E. Margariti Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis Hepatology 58 2013 653A [abstract 933]
46. Y.C. Chen, W.J. Jeng, R.N. Chien, and Y.F. Liaw Hepatocellular carcinoma development in HBe-negative hepatitis B cirrhotic patients with entecavir treatment J Hepatol 58 2013 S215 [abstract 521]
47. V.W. Wong, S.L. Chan, F. Mo, T.C. Chan, H.H. Loong, and G.L. Wong Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers J Clin Oncol 28 2010 1660 1665
48. M.F. Yuen, Y. Tanaka, D.Y. Fong, J. Fung, D.K. Wong, and J.C. Yuen Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B J Hepatol 50 2009 80 88
49. G. Papatheodoridis, G. Dalekos, V. Sypsa, C. Yurdaydin, M. Buti, and J. Goulis PAGE-B: risk score for hepatocellular carcinoma (HCC) development in Caucasian chronic hepatitis B (CHB) patients receiving entecavir (ETV) or tenofovir (TDF) J Hepatol 60 2014 S435 [abstract P1075]
50. M.H. Lee, H.I. Yang, J. Liu, R. Batrla-Utermann, C.L. Jen, and U.H. Iloeje Prediction models of long-term cirrhosis and HCC risk in chronic hepatitis B patients: risk scores integrating host and virus profiles Hepatology 58 2013 546 554
51. H.L. Chan Identifying hepatitis B carriers at low risk for hepatocellular carcinoma Gastroenterology 142 2012 1057 1060
52. K.S. Jung, S.U. Kim, S.H. Ahn, Y.N. Park, Y. Kim do, and J.Y. Park Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan) Hepatology 53 2011 885 894
53. G.L. Wong, H.L. Chan, H.Y. Chan, P.C. Tse, Y.K. Tse, and C.W. Mak Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment Gastroenterology 144 2013 933 944
54. G.V. Papatheodoridis, G. Dalekos, C. Yurdaydin, J. Goulis, P. Arends, and M. Buti Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF) Hepatology 58 2013 [abstract 302A]
55. I. Kim, J. Moon, S. Kim, S. Kim, S. Lee, and S. Lee Duration of virologic response is a significant factor for disease progression and hepatocellular carcinoma development in patients with chronic hepatitis B during oral nucleos(t)ide analogues therapy Hepatology 58 2013 628A [abstract 885]
56. Y.C. Hsu, C.Y. Wu, H.Y. Lane, C.Y. Chang, C.M. Tai, and C.H. Tseng Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B J Antimicrob Chemother 69 2014 1920 1927
57. K.P. Maier Cirrhosis of the liver as a precancerous condition Praxis 87 1998 1462 1465
58. C.L. Lai, and M.F. Yuen Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy Hepatology 57 2013 399 408
59. J.D. Yang, W.R. Kim, R. Coelho, T.A. Mettler, J.T. Benson, and S.O. Sanderson Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma Clin Gastroenterol Hepatol 9 2011 64 70
60. S.C. Gordon, L.E. Lamerato, L.B. Rupp, J. Li, S.D. Holmberg, and A.C. Moorman Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population Clin Gastroenterol Hepatol 12 2014 885 893
61. C. Wong, and K. Goh Chronic hepatitis B infection and liver cancer Biomed Imaging Interv J 2 2006 e7
62. G.V. Papatheodoridis, S. Manolakopoulos, G. Touloumi, G. Vourli, M. Raptopoulou-Gigi, and I. Vafiadis-Zoumbouli Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study Gut 60 2011 1109 1116
63. G. Kim, J. An, D. Suh, Y. Lim, and S. Han Risk of hepatocellular carcinoma after HBsAg seroclearance associated with nucleoside analogue therapy in patients with chronic hepatitis B Hepatology 58 2013 629A [abstract 889]
64. E. Orito, A. Kusakabe, C. Hasebe, M. Kurosaki, N. Izumi, and Y. Osaki Risk factors associated with development of hepatocellular carcinoma during nucleotide analogs therapy for patients with chronic hepatitis B virus infection Hepatology 58 2013 676A [abstract 975]
65. H.W. Lee, E.J. Yoo, B.K. Kim, S.U. Kim, J.Y. Park, and Y. Kim do Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy Am J Gastroenterol 109 2014 1241 1249
66. J.H. Kao Risk stratification of HBV infection in Asia-Pacific region Clin Mol Hepatol 20 2014 223 227